{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:09:52Z","timestamp":1790698192181,"version":"4.1.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,4,16]],"date-time":"2018-04-16T00:00:00Z","timestamp":1523836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,4,16]],"date-time":"2018-04-16T00:00:00Z","timestamp":1523836800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Precision Onc"],"DOI":"10.1038\/s41698-018-0055-0","type":"journal-article","created":{"date-parts":[[2018,4,13]],"date-time":"2018-04-13T15:45:00Z","timestamp":1523634300000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":60,"title":["Recent advances in precision oncology research"],"prefix":"10.1038","volume":"2","author":[{"given":"Ann M.","family":"Bode","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zigang","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,4,16]]},"reference":[{"key":"55_CR1","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/s41698-017-0010-5","volume":"1","author":"AM Bode","year":"2017","unstructured":"Bode, A. M. & Dong, Z. Precision oncology- the future of personalized cancer medicine?. .npj Precision Oncol. 1, 2, https:\/\/doi.org\/10.1038\/s41698-017-0010-5 (2017).","journal-title":".npj Precision Oncol."},{"key":"55_CR2","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","volume":"377","author":"GV Long","year":"2017","unstructured":"Long, G. V. et al. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N. Engl. J. Med. 377, 1813\u20131823 (2017).","journal-title":"N. Engl. J. Med."},{"key":"55_CR3","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1093\/annonc\/mdx707","volume":"29","author":"LR Yates","year":"2018","unstructured":"Yates, L. R. et al. The European Society for Medical Oncology (ESMO) Precision Medicine Glossary. Ann. Oncol. 29, 30\u201335 (2018).","journal-title":"Ann. Oncol."},{"key":"55_CR4","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1172\/JCI76094","volume":"125","author":"S Gross","year":"2015","unstructured":"Gross, S., Rahal, R., Stransky, N., Lengauer, C. & Hoeflich, K. P. Targeting cancer with kinase inhibitors. J. Clin. Invest. 125, 1780\u20131789 (2015).","journal-title":"J. Clin. Invest."},{"key":"55_CR5","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646\u2013674 (2011).","journal-title":"Cell"},{"key":"55_CR6","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/s41698-017-0016-z","volume":"1","author":"SH Shin","year":"2017","unstructured":"Shin, S. H. Bode, A. M. & Dong, Z. Precision medicine: the foundation of future cancer therapeutics. npj Precision Oncol. 1, 12, https:\/\/doi.org\/10.1038\/s41698-017-0016-z (2017).","journal-title":"npj Precision Oncol."},{"key":"55_CR7","doi-asserted-by":"publisher","first-page":"57","DOI":"10.4103\/0976-500X.184768","volume":"7","author":"KV Chary","year":"2016","unstructured":"Chary, K. V. Expedited drug review process: fast, but flawed. J. Pharmacol. Pharmacother. 7, 57\u201361 (2016).","journal-title":"J. Pharmacol. Pharmacother."},{"key":"55_CR8","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/s41698-017-0032-z","volume":"1","author":"SH Shin","year":"2017","unstructured":"Shin, S. H., Bode, A. M. & Dong, Z. Addressing the challenges of applying precision oncology. npj Precision Oncol. 1, 28, https:\/\/doi.org\/10.1038\/s41698-017-0032-z (2017).","journal-title":"npj Precision Oncol."},{"key":"55_CR9","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41698-017-0031-0","volume":"1","author":"YA Lyons","year":"2017","unstructured":"Lyons, Y. A. Wu, S. Y. Overwijk, W. W. Baggerly, K. A. & Sood, A. K. Immune cell profiling in cancer: molecular approaches to cell-specific identification. npj Precision Oncol. 1, 26, https:\/\/doi.org\/10.1038\/s41698-017-0031-0 (2017).","journal-title":"npj Precision Oncol."},{"key":"55_CR10","unstructured":"Grupp, S. A. et al. Analysis of a global registration trial of the efficacy and safety of CTL019 in pediatric and young adults with relapsed\/refractory acute lymphoblastic leukemia. Blood 128."},{"key":"55_CR11","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1182\/blood-2016-04-711903","volume":"128","author":"SA Ali","year":"2016","unstructured":"Ali, S. A. et al. T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma. Blood 128, 1688\u20131700 (2016).","journal-title":"Blood"},{"key":"55_CR12","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1126\/science.aaa1348","volume":"348","author":"NA Rizvi","year":"2015","unstructured":"Rizvi, N. A. et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348, 124\u2013128 (2015).","journal-title":"Science"},{"key":"55_CR13","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s12929-017-0329-9","volume":"24","author":"Y Iwai","year":"2017","unstructured":"Iwai, Y., Hamanishi, J., Chamoto, K. & Honjo, T. Cancer immunotherapies targeting the PD-1 signaling pathway. J. Biomed. Sci. 24, 26 (2017).","journal-title":"J. Biomed. Sci."},{"key":"55_CR14","doi-asserted-by":"publisher","first-page":"561","DOI":"10.3389\/fphar.2017.00561","volume":"8","author":"HO Alsaab","year":"2017","unstructured":"Alsaab, H. O. et al. PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome. Front. Pharmacol. 8, 561 (2017).","journal-title":"Front. Pharmacol."},{"key":"55_CR15","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.coph.2015.05.011","volume":"23","author":"J Sunshine","year":"2015","unstructured":"Sunshine, J. & Taube, J. M. PD-1\/PD-L1 inhibitors. Curr. Opin. Pharmacol. 23, 32\u201338 (2015).","journal-title":"Curr. Opin. Pharmacol."},{"key":"55_CR16","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1056\/NEJMoa1706450","volume":"377","author":"M Robson","year":"2017","unstructured":"Robson, M. et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N. Engl. J. Med. 377, 523\u2013533 (2017).","journal-title":"N. Engl. J. Med."},{"key":"55_CR17","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1038\/nature23657","volume":"548","author":"V Garcia-Lopez","year":"2017","unstructured":"Garcia-Lopez, V. et al. Molecular machines open cell membranes. Nature 548, 567\u2013572 (2017).","journal-title":"Nature"},{"key":"55_CR18","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1038\/nbt.4071","volume":"36","author":"S Li","year":"2018","unstructured":"Li, S. et al. A DNA nanorobot functions as a cancer therapeutic in response to a molecular trigger in vivo. Nat. Biotechnol. 36, 258\u2013264 (2018).","journal-title":"Nat. Biotechnol."},{"key":"55_CR19","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1038\/ncb3596","volume":"19","author":"E Giampazolias","year":"2017","unstructured":"Giampazolias, E. et al. Mitochondrial permeabilization engages NF-kappaB-dependent anti-tumour activity under caspase deficiency. Nat. Cell Biol. 19, 1116\u20131129 (2017).","journal-title":"Nat. Cell Biol."},{"key":"55_CR20","doi-asserted-by":"publisher","first-page":"2535","DOI":"10.1001\/jama.2015.16669","volume":"314","author":"R Stupp","year":"2015","unstructured":"Stupp, R. et al. Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma: a randomized clinical trial. JAMA 314, 2535\u20132543 (2015).","journal-title":"JAMA"},{"key":"55_CR21","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1056\/NEJMoa1611977","volume":"376","author":"JR Perry","year":"2017","unstructured":"Perry, J. R. et al. Short-course radiation plus temozolomide in elderly patients with glioblastoma. N. Engl. J. Med. 376, 1027\u20131037 (2017).","journal-title":"N. Engl. J. Med."},{"key":"55_CR22","doi-asserted-by":"publisher","DOI":"10.1212\/NXG.0000000000000164","volume":"3","author":"KO Wrzeszczynski","year":"2017","unstructured":"Wrzeszczynski, K. O. et al. Comparing sequencing assays and human-machine analyses in actionable genomics for glioblastoma. Neurol. Genet. 3, e164 (2017).","journal-title":"Neurol. Genet."},{"key":"55_CR23","doi-asserted-by":"publisher","first-page":"224ra224","DOI":"10.1126\/scitranslmed.3007094","volume":"6","author":"C Bettegowda","year":"2014","unstructured":"Bettegowda, C. et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci. Transl. Med 6, 224ra224 (2014).","journal-title":"Sci. Transl. Med"},{"key":"55_CR24","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.lungcan.2015.10.004","volume":"90","author":"KS Thress","year":"2015","unstructured":"Thress, K. S. et al. EGFR mutation detection in ctDNA from NSCLC patient plasma: a cross-platform comparison of leading technologies to support the clinical development of AZD9291. Lung. Cancer 90, 509\u2013515 (2015).","journal-title":"Lung. Cancer"},{"key":"55_CR25","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/s41698-017-0039-5","volume":"1","author":"E Heitzer","year":"2017","unstructured":"Heitzer, E. Perakis, S. Geigl, J. B. & Speicher, M. R. The potential of liquid biopsies for the early detection of cancer. npj Precision Oncol. 1, 36, https:\/\/doi.org\/10.1038\/s41698-017-0039-5 (2017).","journal-title":"npj Precision Oncol."}],"container-title":["npj Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41698-018-0055-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-018-0055-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-018-0055-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T12:25:59Z","timestamp":1671625559000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41698-018-0055-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,16]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["55"],"URL":"https:\/\/doi.org\/10.1038\/s41698-018-0055-0","relation":{},"ISSN":["2397-768X"],"issn-type":[{"value":"2397-768X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,16]]},"assertion":[{"value":"13 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"11"}}